Growblox Sciences Inc (OTCMKTS:GBLX) Is Making Positive Strides

For most people that support the legalization of cannabis, the support is rooted in being free to use cannabis recreationally without the threat of being arrested by the local police, or being mugged by the illegal local pot dealer on the street corner. The cannabis legalization revolution now allows those who choose to use cannabis to do so freely and openly without legal repercussion, and those who want to grow and sell it, to do so legally within regulated standards, and make a great profit. The government receives increased tax revenues, and the violent criminal drug dealers go broke. This is a win-win for everyone in the cannabis space.Perhaps the group that stands to benefit the most are those that suffer from ailments for which there are no cures, or medications that help relieve symptoms. The cannabis revolution has opened up an entire industry with the sole purpose of helping those with medical needs. Pharmaceutical companies have only begun to scratch the surface of what potential medical breakthroughs may be possible with cannabis.Growblox Sciences, Inc. (OTCMKTS:GBLX) is one such company. It is a diverse vertically integrated cannabis company, focused on cultivation as well as biopharmaceutical research and development. The Company's goal is creating safe, standardized, pharmaceutical-grade, cannabinoid therapies that target a variety of medical conditions. The company has developed a technology that allows for the cultivation of cannabis strains controlled both locally and remotely down to the most minute detail, ensuring identical genetic structure from plant to plant in each grow batch. It has also developed a post-initial grow infrastructure that fosters this identical genetic structure until maturity.Last month, GB Sciences, Inc. announced filing the second in a series of patent applications for life science inventions by its wholly-owned subsidiary, Growblox Life Sciences, LLC. The current provisional patent application covers cannabinoid-containing complex mixtures ("CCCM") capable of preventing and treating a spectrum of inflammatory disorders. The application focuses on the use of CCCM to disrupt the signaling pathways in certain immune cells that lead to the initiation and maintenance of inflammatory responses. Both common and uncommon inflammatory disorders, ranging from chronic arthritis to acute responses to insect stings, are likely to be effectively targeted by this therapeutic approach.

John Poss, CEO, GB Sciences states: "GB Sciences is committed to developing cannabis-based therapies for inflammatory disorders that affect large numbers of patients (arthritis, dermatitis, allergic asthma, eczema, IBD, Crohn's disease, etc.). Our CCCM products will be developed to the same efficacy and safety standards as other commercially available anti-inflammatory therapies; however, cannabis-based medicines often have more favorable side effect profiles than traditional pharmaceuticals."

In January, GB Sciences announced the receipt of the State Registration Certificate for its 28,000 sq. ft. cannabis cultivation facility located in Las Vegas, Clark County, Nevada, which now allows the facility to produce cannabis.

"The receipt of the registration certificate is a monumental step for the Company as it will allow us to move forward in a new, cash flow generating, phase. The team and I are extremely excited about the opportunities ahead," said John Poss, GB Sciences' CEO.

Last December, GB Sciences, Inc. announced that it had licensed intellectual property from Makai Biotechnology, LLC. The patent underlying the license was issued by the USPTO in July of 2015, and claims therapeutic methods for the treatment of cardiac hypertrophy and associated pathologies through regulation of the cannabinoid receptor, TRPV1. TRPV1 can be regulated therapeutically by plant-based cannabinoids, which creates a plethora of potentially new therapeutic agents for the treatment of cardiac hypertrophy and heart failure.

GB Sciences CEO John Poss remarked: "This license is an important step in our Company's march to successful drug discovery. We are very proud of Dr. Small-Howard and her team, and we expect results from this effort that will enable the company to do well by doing good for literally millions of cardiac patients around the world."

Growblox Sciences’ stock is trading in a range with support at about $.28, and most trading taking place below $.40, with a couple of short forays above $.40, one in November of 2016, and in February of 2017. It is currently trading at $.34. Volume is steady and strong. The financials show that the company is still pre-revenue. Current market capitalization stands at $38.8 million, on 110.9 million shares outstanding as of March 13, 2017Like any other pharmaceutical business, bringing new drugs and therapies to market are a very long-term, and expensive endeavors. GB Sciences is making strides. Once its products hit the market, growth will follow. We will be updating our subscribers as soon as we know more. For the latest updates on GBLX, sign up below!Disclosure: We have no position in GBLX and have not been compensated for this article.